Marbofloxacin (Zeniquin)

Marbofloxacin, marketed under the brand name Zeniquin, is a third-generation fluoroquinolone antibiotic that represents an important therapeutic option for treating bacterial infections in rabbits. This veterinary-specific antimicrobial agent belongs to the fluoroquinolone class, which is recognized as one of the safer antibiotic groups for use in rabbits. This safety profile is critically important because rabbits possess an extremely sensitive gastrointestinal microbiome that can be fatally disrupted by many antibiotics commonly used in dogs and cats. Marbofloxacin offers rabbit-savvy veterinarians another valuable tool for combating bacterial infections without the devastating enterotoxemia risks associated with antibiotics like amoxicillin, clindamycin, and oral penicillins.

The mechanism of action of marbofloxacin involves inhibition of bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. By interfering with these critical processes, marbofloxacin exerts a bactericidal effect against susceptible organisms. The drug demonstrates broad-spectrum activity against many gram-negative bacteria and selected gram-positive organisms. Particularly relevant to rabbit medicine is its activity against Pasteurella multocida and other pathogens commonly responsible for respiratory, skin, and soft tissue infections in domestic rabbits.

Marbofloxacin exhibits favorable pharmacokinetic properties including good oral bioavailability, extensive tissue distribution, and achievement of therapeutic concentrations at common infection sites. The drug penetrates well into respiratory tissues, skin and soft tissue structures, and urinary tract tissues. Its relatively long half-life in some species may allow for once-daily dosing in certain situations, though dosing intervals in rabbits should be determined by a veterinarian familiar with lagomorph pharmacology. As a veterinary-labeled product, Zeniquin is formulated for animal use and is available in convenient tablet sizes suitable for various patient weights.

As with all antibiotics used in rabbits, marbofloxacin should only be administered under the direct supervision of a veterinarian experienced in rabbit medicine. Appropriate patient selection, accurate weight-based dosing, and completion of the full prescribed treatment course are essential for achieving therapeutic success while minimizing the risk of treatment failure or resistance development. Rabbit owners should never administer marbofloxacin or any other antibiotic without explicit veterinary guidance and should monitor their rabbit carefully for any adverse effects during treatment.

Marbofloxacin is indicated for the treatment of bacterial infections caused by susceptible organisms in rabbits. Skin and soft tissue infections represent one of the primary applications for marbofloxacin in rabbit medicine. Bacterial dermatitis, wound infections, abscesses, and cellulitis can occur secondary to trauma, bite wounds, environmental factors, or underlying skin conditions. Marbofloxacin achieves good concentrations in skin and soft tissue structures, making it effective for treating superficial and deeper soft tissue infections caused by susceptible bacteria.

Respiratory tract infections constitute another important indication for marbofloxacin use in rabbits. Upper respiratory infections caused by Pasteurella multocida, commonly known as snuffles, are among the most prevalent bacterial diseases in domestic rabbits. These infections may manifest as nasal discharge, sneezing, conjunctivitis, and facial swelling. Lower respiratory infections including pneumonia and bronchitis can also occur and may present with more serious symptoms such as labored breathing, decreased activity, and inappetence. Marbofloxacin's penetration into respiratory tissues supports its effectiveness for both upper and lower respiratory tract infections.

Urinary tract infections in rabbits may be treated with marbofloxacin when caused by susceptible pathogens. Bacterial cystitis presents with clinical signs that may include frequent urination, straining, blood-tinged urine, and urinary incontinence. Gram-negative bacteria such as Escherichia coli commonly cause urinary infections in rabbits and are typically susceptible to fluoroquinolone antibiotics. The drug achieves good urinary concentrations, contributing to its effectiveness for urinary tract pathogens. Culture and sensitivity testing can confirm marbofloxacin susceptibility and guide treatment decisions.

Marbofloxacin may be selected over other fluoroquinolones based on veterinary preference, specific susceptibility patterns, drug availability, or cost considerations. In some cases, marbofloxacin may demonstrate superior activity against certain bacterial strains compared to older fluoroquinolones, making it a preferred choice when culture results indicate such advantages. The drug may also be chosen when previous treatment with other antibiotics has failed or when resistance to other agents is documented or suspected.

Additional potential applications include treatment of otitis when systemic antibiotic therapy is indicated, post-surgical infection prophylaxis in selected high-risk cases, and management of secondary bacterial infections complicating other disease processes. Rabbits with underlying conditions such as dental disease, immunosuppression, or chronic illness may develop opportunistic bacterial infections requiring antibiotic intervention. Your veterinarian will evaluate your rabbit's specific situation to determine whether marbofloxacin is the most appropriate antibiotic choice and will prescribe accordingly.

Marbofloxacin dosing in rabbits must be established by a veterinarian experienced in rabbit medicine who can evaluate your individual patient and prescribe appropriately. Dosing requirements in rabbits differ from those in dogs and cats due to species-specific variations in drug metabolism, distribution, and elimination. Your veterinarian will determine the appropriate dose based on your rabbit's accurately measured body weight, the type and severity of infection, and other relevant clinical factors. Never attempt to calculate or adjust doses without veterinary guidance.

Accurate body weight measurement is essential for safe marbofloxacin dosing in rabbits. The substantial size variation among rabbit breeds means that appropriate doses vary considerably between individuals. Weigh your rabbit using a scale that measures in grams, particularly for smaller breeds where minor weight variations represent significant percentages of total body weight. Provide your veterinarian with a current accurate weight, and reweigh during extended treatment courses as illness-related weight changes may necessitate dose adjustments.

Marbofloxacin tablets are the most commonly prescribed formulation for outpatient treatment of rabbits. Zeniquin tablets are scored, which can facilitate accurate division when fractional tablets are prescribed, though liquid compounded formulations may be preferred for very small rabbits requiring precise small doses. Administer tablets orally, and your veterinarian may suggest crushing tablets and mixing with a small amount of palatable food such as banana or unsweetened applesauce to facilitate administration. Alternatively, tablets can be dissolved in a small amount of water and given via syringe.

Injectable marbofloxacin may be utilized in hospital settings or prescribed for home administration in certain situations. The injectable route may be preferred for rabbits unable to take oral medication, those with gastrointestinal disease affecting drug absorption, or critically ill patients requiring rapid achievement of therapeutic concentrations. If home injections are prescribed, your veterinarian will demonstrate proper subcutaneous injection technique and provide necessary supplies and instructions.

Treatment duration depends on the type and severity of infection being treated. Uncomplicated infections may require one to two weeks of therapy, while more serious or chronic infections often necessitate longer treatment courses of three to four weeks or more. Complete the entire prescribed course of marbofloxacin even if your rabbit appears to improve before the medication is finished. Stopping antibiotic therapy prematurely can result in relapse and may contribute to the development of antibiotic-resistant bacteria.

If a dose is missed, administer it as soon as you remember unless the next scheduled dose is approaching. Never double doses to make up for missed administrations. Contact your veterinarian if multiple doses are missed or if you have questions about how to proceed. Throughout treatment, monitor your rabbit's appetite, fecal output, and general demeanor daily, reporting any concerning changes to your veterinarian promptly.

Marbofloxacin is generally well-tolerated in rabbits when administered at appropriate doses under veterinary supervision. The fluoroquinolone class represents one of the safer antibiotic groups for rabbit use compared to many other antibiotic classes that can cause fatal gastrointestinal complications. However, as with all medications, marbofloxacin can potentially cause adverse effects that owners should understand and monitor for during the treatment period.

Common mild side effects observed during marbofloxacin therapy may include temporary changes in appetite and minor alterations in fecal characteristics. Some rabbits experience slightly decreased food interest during the initial days of treatment, which typically resolves as the body adjusts to the medication. Fecal pellets may become somewhat smaller or softer during therapy. These mild effects are usually transient and do not require discontinuation of treatment. Maintaining unlimited access to grass hay and ensuring adequate hydration helps support normal gastrointestinal function during antibiotic therapy.

Moderate side effects warranting veterinary attention include more pronounced appetite reduction lasting beyond the first few days, significantly decreased fecal pellet production, persistent soft stool, or changes in cecotrope production or consumption. While marbofloxacin is considered safer for rabbit gut flora than many other antibiotics, it can still occasionally affect gastrointestinal function. Any rabbit that refuses food for more than twelve hours or shows notably reduced fecal output should be evaluated by a veterinarian, as these can be early indicators of developing gastrointestinal stasis.

Serious side effects requiring immediate veterinary attention include complete loss of appetite, absence of fecal pellet production, watery diarrhea, visible abdominal distension, teeth grinding indicating pain, hunched posture, extreme lethargy, or collapse. While serious adverse reactions are less common with fluoroquinolones than with certain other antibiotics, gastrointestinal complications in rabbits can progress rapidly and become life-threatening. Severe gastrointestinal stasis or dysbiosis requires urgent veterinary intervention including fluid therapy, motility support, and potentially assisted feeding.

Additional potential side effects reported with fluoroquinolone antibiotics in various species include effects on developing cartilage in young growing animals, which may warrant consideration when treating juvenile rabbits. Rare neurological effects have been reported with fluoroquinolones in some species but appear uncommon in rabbits at appropriate doses. Hypersensitivity reactions, while rare, can occur with any medication and may present as facial swelling, hives, difficulty breathing, or other acute allergic symptoms requiring emergency care. Report any unexpected symptoms during marbofloxacin treatment to your veterinarian.

Marbofloxacin is contraindicated in rabbits with known hypersensitivity or previous allergic reaction to marbofloxacin or other fluoroquinolone antibiotics. Cross-reactivity among fluoroquinolones can occur, meaning that a rabbit with a documented adverse reaction to enrofloxacin, ciprofloxacin, or orbifloxacin may also react to marbofloxacin. Signs of previous hypersensitivity may have included facial swelling, skin reactions, respiratory distress, or collapse following fluoroquinolone administration. Inform your veterinarian of any previous adverse drug reactions before starting marbofloxacin therapy.

Caution is advised when considering marbofloxacin use in young growing rabbits due to potential effects on developing cartilage. Fluoroquinolone antibiotics have been associated with cartilage abnormalities in juvenile animals of some species. While significant cartilage problems appear uncommon in rabbits, some veterinarians prefer alternative antibiotics when treating very young kits if appropriate options exist. The decision to use marbofloxacin in juvenile rabbits involves weighing the severity of the infection against potential risks, considering available alternatives, and applying clinical judgment.

Rabbits with impaired kidney function may require dose adjustments or selection of alternative antibiotics. Renal impairment affects drug elimination and can lead to accumulation of marbofloxacin with potential for increased adverse effects. Your veterinarian may recommend blood tests to evaluate kidney function before prescribing marbofloxacin, particularly in older rabbits or those with known or suspected renal disease. Hepatic impairment may similarly affect drug metabolism and should be considered in rabbits with known liver disease or those receiving other medications that affect liver function.

The use of marbofloxacin in pregnant or lactating rabbits requires careful evaluation of risks versus benefits. Limited data exists regarding marbofloxacin safety during rabbit pregnancy and lactation. Fluoroquinolones cross the placenta and are excreted in milk, raising theoretical concerns about effects on developing offspring. If antibiotic therapy is essential in a pregnant or nursing rabbit, your veterinarian will consider whether alternative antibiotics with better-established safety profiles might be appropriate. Rabbits with active gastrointestinal disturbance, recent antibiotic-associated complications, or concurrent severe illness require careful evaluation before initiating any antibiotic therapy.

Marbofloxacin can interact with various medications, supplements, and dietary factors, making comprehensive disclosure of all substances your rabbit receives essential for safe prescribing. Drug interactions may reduce marbofloxacin effectiveness, increase toxicity risk, or alter the effects of concurrently administered medications. Provide your veterinarian with a complete list of all prescription medications, over-the-counter products, supplements, and herbal preparations your rabbit is receiving.

Oral absorption of marbofloxacin is significantly impaired by concurrent administration of products containing divalent and trivalent metal cations. Calcium, magnesium, aluminum, iron, and zinc form chelation complexes with fluoroquinolones in the gastrointestinal tract, dramatically reducing drug absorption and potentially causing treatment failure. If your rabbit receives calcium supplements, mineral supplements, or antacid products, these must be administered separately from marbofloxacin, typically at least two hours before or four to six hours after the antibiotic dose. Consult your veterinarian regarding timing of all supplements during marbofloxacin treatment.

The concurrent use of marbofloxacin with other antibiotics requires careful veterinary consideration. While combination antibiotic therapy may occasionally be warranted for complex or resistant infections, combining multiple antibiotics increases the risk of gastrointestinal disturbance in rabbits. Critically, any concurrent antibiotic must also be safe for rabbit use. Never add antibiotics to your rabbit's treatment regimen without explicit veterinary guidance. Antibiotics that are dangerous or fatal to rabbits include amoxicillin, ampicillin, clindamycin, lincomycin, erythromycin, oral penicillins, and most cephalosporins. These drugs can cause fatal enterotoxemia even in single doses.

Marbofloxacin may interact with certain anti-inflammatory medications and other drugs affecting the central nervous system. Some studies in other species have suggested increased seizure risk when fluoroquinolones are combined with nonsteroidal anti-inflammatory drugs, though this appears to be uncommon. If your rabbit is receiving meloxicam or other pain medications concurrently with marbofloxacin, inform your veterinarian so appropriate monitoring can be implemented. Medications affecting hepatic enzyme systems may potentially alter marbofloxacin metabolism.

Probiotic supplementation is commonly recommended during antibiotic therapy in rabbits and is generally compatible with marbofloxacin use. Probiotics help support beneficial gut bacteria populations that may be affected even by relatively safe antibiotics. For optimal benefit, administer probiotics separately from antibiotics by at least two hours to give the probiotic organisms a chance to establish before antibiotic exposure. Your veterinarian can recommend appropriate probiotic products and timing schedules during marbofloxacin treatment.

The most important precaution when using antibiotics in rabbits is ensuring the selected drug belongs to a safe antibiotic class for this species. Marbofloxacin is a fluoroquinolone antibiotic, which is considered safe for rabbit use. However, rabbit owners must understand that many antibiotics routinely used in dogs and cats can cause fatal gastrointestinal complications in rabbits. Antibiotics that should never be given to rabbits include amoxicillin, ampicillin, clindamycin, lincomycin, erythromycin, oral penicillins, most cephalosporins, and tylosin. These drugs disrupt the sensitive cecal microbiome and can cause rapidly fatal enterotoxemia. Always verify with a rabbit-experienced veterinarian that any prescribed antibiotic is rabbit-safe.

Accurate dosing based on precise body weight is essential for safe and effective marbofloxacin therapy. The wide range of body sizes among rabbit breeds means that appropriate doses vary considerably between individuals. A dose suitable for a large Flemish Giant would represent a massive overdose for a small Netherland Dwarf. Weigh your rabbit on a scale measuring in grams, particularly for smaller breeds, and ensure your veterinarian uses this accurate weight for dose calculations. Reweigh during extended treatment courses, as illness-related weight changes may necessitate dose adjustments.

Vigilant monitoring of gastrointestinal function throughout marbofloxacin treatment is essential for early detection of potential problems. Observe your rabbit's appetite, water consumption, and fecal pellet production daily. Normal healthy rabbits produce abundant firm, round fecal pellets and consume their nutrient-rich cecotropes. A decrease in fecal output, production of abnormally small pellets, soft or misshapen stool, or evidence of reduced cecotrope production should prompt veterinary consultation. Any significant reduction in appetite lasting more than twelve hours is concerning and warrants immediate veterinary attention.

Marbofloxacin should be prescribed only when bacterial infection is confirmed or strongly suspected. Inappropriate antibiotic use for viral conditions or as general preventive measures exposes rabbits to unnecessary medication risks and contributes to antibiotic resistance. Ensure you understand the diagnosis and treatment rationale when marbofloxacin is prescribed. Complete the full treatment course even if improvement occurs before the medication is finished, as stopping prematurely risks relapse and resistance development.

Special considerations apply to certain rabbit populations. Geriatric rabbits may have reduced organ function affecting drug metabolism and elimination. Immunocompromised rabbits may require extended treatment courses. Rabbits with chronic conditions such as dental disease, E. cuniculi infection, or heart disease may need modified treatment approaches. Pregnant and nursing rabbits require careful risk-benefit evaluation before antibiotic use. Provide complete health history information to your veterinarian to enable appropriate prescribing and monitoring.

Proper storage of marbofloxacin maintains medication effectiveness and safety throughout the treatment course. Zeniquin tablets should be stored at controlled room temperature, typically between 59 and 86 degrees Fahrenheit, in a dry location protected from excessive heat, moisture, and light. Keep tablets in the original container with the lid securely closed. Avoid storing medications in bathrooms where humidity from bathing can accelerate degradation, and keep away from heat-generating appliances and direct sunlight.

Injectable marbofloxacin formulations should be stored according to manufacturer specifications, typically at controlled room temperature protected from light. Injectable solutions should remain clear and particle-free. Do not use injectable medication that appears cloudy, discolored, or contains visible precipitates, as these may indicate degradation. If you are administering injectable marbofloxacin at home, your veterinarian will provide specific storage and handling instructions for the medication and injection supplies, including proper disposal of used needles and syringes.

If your veterinarian prescribes a compounded formulation of marbofloxacin, such as an oral liquid suspension for easier dosing of small rabbits, follow the storage instructions provided by the compounding pharmacy. Compounded medications often require specific storage conditions and have shorter beyond-use dates than manufactured products. Note the expiration or beyond-use date and do not use medication beyond this time. Shake liquid suspensions thoroughly before each dose to ensure uniform drug distribution.

All marbofloxacin formulations must be stored securely out of reach of rabbits, children, and other household pets. Rabbits allowed free access to areas where medications are stored may chew through containers and accidentally ingest dangerous amounts. Store rabbit medications separately from medications for other pets to prevent accidental administration of inappropriate drugs, as many medications safe for dogs and cats are dangerous to rabbits. Dispose of unused or expired marbofloxacin through veterinary or pharmacy take-back programs rather than placing in regular trash or flushing, which can contaminate the environment.

Marbofloxacin can be used safely across the full spectrum of rabbit breeds, but the substantial size variation among breeds necessitates careful attention to accurate weight-based dosing. Rabbit breeds range from diminutive dwarf varieties weighing under three pounds to giant breeds exceeding fifteen pounds. This five-fold or greater variation in body weight means appropriate marbofloxacin doses differ enormously between individuals. Accurate dosing is essential for therapeutic effectiveness and safety regardless of breed.

Dwarf breeds including Netherland Dwarfs, Holland Lops, Mini Rex, Polish, Britannia Petites, and Jersey Woolies require especially precise dosing due to their small body size. In these tiny rabbits, a weight measurement error of even a few ounces represents a significant percentage of total body weight and can substantially affect dose accuracy. Weigh dwarf rabbits on a gram scale for maximum precision. Liquid formulations or specifically compounded preparations are often preferred for dwarf breeds because they allow more accurate measurement of small doses than tablet division. Some veterinarians recommend having marbofloxacin compounded into concentrations appropriate for precise small-volume dosing.

Giant breeds including Flemish Giants, Continental Giants, British Giants, Giant Chinchillas, and French Lops require larger absolute doses of marbofloxacin to achieve therapeutic blood levels. Ensure adequate medication quantity is dispensed for the complete treatment course, as larger rabbits consume proportionally more medication. Giant breeds are predisposed to certain musculoskeletal conditions including spondylosis and hock problems, and while cartilage effects from fluoroquinolones appear primarily concerning in young growing animals, existing joint conditions may be considered when planning treatment. Giant rabbits that become less mobile during illness may need modified handling and medication administration techniques.

Lop-eared breeds are anatomically predisposed to ear problems due to their pendulous ear carriage, which impairs ear canal ventilation and drainage. When marbofloxacin is prescribed for ear-related infections in lop breeds, extended treatment courses may be necessary. Rex breeds with their distinctive velvet fur may experience increased susceptibility to certain skin conditions, and when bacterial skin infections require treatment, marbofloxacin may be selected based on culture and sensitivity results. Angora, Jersey Wooly, and other wool breeds present challenges with topical medication application due to dense coats, making systemic antibiotics like marbofloxacin particularly valuable when treating bacterial infections in these breeds.

Several alternative fluoroquinolone antibiotics are available that share similar mechanisms and safety profiles with marbofloxacin. Enrofloxacin, sold as Baytril, is perhaps the most widely used fluoroquinolone in rabbit medicine and offers a similar spectrum of activity. Ciprofloxacin, a human-labeled fluoroquinolone, is commonly used off-label in rabbits and is actually the primary metabolite of enrofloxacin. Orbifloxacin, marketed as Orbax, represents another fluoroquinolone option for rabbit patients. Selection among fluoroquinolones may depend on veterinary preference, drug availability, cost factors, or specific bacterial susceptibility patterns determined by culture testing.

When fluoroquinolones are not appropriate due to resistance, previous adverse reactions, or other factors, several alternative antibiotic classes are considered safe for rabbit use. Trimethoprim-sulfonamide combinations, available as Bactrim, Septra, or generic equivalents, are frequently prescribed for various bacterial infections in rabbits. Chloramphenicol is an effective broad-spectrum option for serious infections, though handler precautions are necessary due to rare but serious human health risks. Azithromycin is safe for rabbits unlike related macrolide antibiotics such as erythromycin. Metronidazole is valuable for anaerobic bacterial infections and certain protozoal conditions. Injectable penicillin G can be used safely for certain infections, particularly chronic Pasteurella-associated abscesses, but oral penicillins must never be given to rabbits.

Supportive therapies complement antibiotic treatment and help maintain gastrointestinal health during therapy. Probiotic supplements containing rabbit-appropriate beneficial bacteria support the gut microbiome during antibiotic use and should be administered separately from antibiotics by several hours. Critical Care or equivalent recovery formulas provide nutritional support for rabbits with decreased appetite. Unlimited grass hay must remain available throughout treatment to support normal gut motility and function. Subcutaneous fluids may be recommended for rabbits showing dehydration. Simethicone can help relieve gas accumulation that sometimes occurs during illness or treatment. Your veterinarian should guide all decisions regarding supportive care and any antibiotic substitutions, as selecting inappropriate antibiotics can have fatal consequences in rabbits.